Phren Life Sciences

Phren Life Sciences is a biotechnology company focused on developing next-generation therapies for neuropsychiatric and neurodegenerative disorders. The company utilizes a proprietary discovery platform that combines advanced computational modeling with high-throughput screening to identify novel small molecule modulators of G protein-coupled receptors (GPCRs). Their primary research efforts target cognitive impairment associated with schizophrenia and the behavioral symptoms of Alzheimer's and Parkinson's diseases. By focusing on highly specific receptor subtypes, Phren aims to improve therapeutic efficacy while minimizing the side effects common in traditional CNS medications. The company is currently advancing several lead compounds through pre-clinical validation.